5:13 PM
 | 
May 29, 2013
 |  BC Extra  |  Top Story

FDA approves GSK melanoma drugs

FDA approved a pair of NDAs from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for Tafinlar dabrafenib and Mekinist trametinib as monotherapies to treat metastatic or unresectable melanoma. Tafinlar, an oral BRAF protein kinase inhibitor, is approved to treat melanoma with BRAF V600E mutations as detected by an FDA-approved test....

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >